Novartis Japan Looks To Capitalize On Drug Approval Spurt, Submits NDA For Everolimus
This article was originally published in The Pink Sheet Daily
Executive Summary
Product launches will follow listing by Japan’s Central Social Insurance Medical Council.
You may also be interested in...
Novartis Sees Opportunities In Financial Crisis, CEO Tells Tokyo Business Group
TOKYO - Novartis CEO Daniel Vasella told an audience in Tokyo last week that "the current [global financial] situation creates opportunities because [Novartis has] a very solid free cash flow and most [Novartis] companies have a solid free cash flow and are not in a highly indebted environment.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues.
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.